22 results
6-K
EX-99.1
IPHA
Innate Pharma
14 May 24
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results
6:07am
-expressing relapsed/refractory PTCL is ongoing and continues to recruit patients.
ANKET® (Antibody-based NK cell Engager Therapeutics):
ANKET®
6-K
EX-99.1
IPHA
Innate Pharma
29 Apr 22
Innate Pharma S.a. 6-K
6:00am
looking to recruit patients across more than 200 centers in the coming months.
Stage III NSCLC:
In 2020, an estimated 2.2 million people were
6-K
EX-99.1
zbr2rluna4k a1a3po
24 Mar 22
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
1dss8nx0n
16 Jun 21
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy
6:30am
6-K
EX-99.1
j32c u46on
9 Jun 21
New Lacutamab Data From Tellomak Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma
6:30am
6-K
EX-99.1
2ofx x6o11ztwoo
9 Feb 21
Innate Pharma Advances Lacutamab Clinical Development Program
6:30am
6-K
EX-99.1
93ysqvo lsbuh7
13 Nov 20
Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sézary Syndrome
6:30am
6-K
EX-99.1
7vxj1qnnye 8l4i2ti98
24 Jun 20
Current report (foreign)
6:30am
20-F
ntw 2lk7js9zx2y
24 Apr 20
Annual report (foreign)
10:43am
6-K
EX-99.1
trpafkz05e81qk
14 Jan 20
French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides
6:30am
6-K
EX-99.1
glvf97co3qc1rv1n
9 Jan 20
Innate Pharma Provides Update from Regulatory Agencies on Lacutamab TELLOMAK Trial
6:30am
6-K
EX-99.1
z5isk6zi7mg
13 Dec 19
Innate Pharma Provides Update on Lacutamab TELLOMAK Trial
6:30am
424B4
t0ska22 5l47zk8p
18 Oct 19
Prospectus supplement with pricing info
4:08pm
F-1/A
61a61jg7d2pmjhv
4 Oct 19
Registration statement (foreign) (amended)
4:56pm
F-1
y3yv8j blith
20 Sep 19
Registration statement (foreign)
4:08pm
DRS/A
7kh h41duwi
30 Aug 19
Draft registration statement (amended)
12:00am